Toll-like receptor 2 ligand and interferon-γ suppress anti-tumor T cell responses by enhancing the immunosuppressive activity of monocytic myeloid-derived suppressor cells

CD11b+Gr1+ myeloid-derived suppressor cells (MDSCs) suppress activation/proliferation of cytotoxic T cells, thereby hindering cancer immunotherapy. MDSCs are increased after adjuvant therapy with toll-like receptor (TLR) 2 ligands, such as Pam2CSK4, in tumor-bearing mice. However, it remains unknown...

Full description

Bibliographic Details
Main Authors: Hiroaki Shime, Akira Maruyama, Sumito Yoshida, Yohei Takeda, Misako Matsumoto, Tsukasa Seya
Format: Article
Language:English
Published: Taylor & Francis Group 2018-01-01
Series:OncoImmunology
Subjects:
Online Access:http://dx.doi.org/10.1080/2162402X.2017.1373231